The 5 Most Interesting Analyst Questions From Biogen’s Q4 Earnings Call

The 5 Most Interesting Analyst Questions From Biogen’s Q4 Earnings Call

Anthony Lee

Fri, February 13, 2026 at 2:36 PM GMT+9 4 min read

In this article:

BIIB

+2.25%

Biogen’s fourth-quarter results were received positively by the market, as the company exceeded Wall Street’s revenue and non-GAAP profit expectations despite a year-over-year decline in sales. Management attributed performance to robust growth in its newer product portfolio, particularly Lekembi, Skyclaris, Xerxuve, and Calcadi, which collectively surpassed $1 billion in annual revenue. CEO Christopher Viehbacher pointed to successful expansion of VUMERITY within the multiple sclerosis segment and highlighted that, “Biogen is functioning and firing on all cylinders, and doing very well,” as the company pivots its commercial focus toward growth products and away from legacy assets.

Is now the time to buy BIIB? Find out in our full research report (it’s free).

Biogen (BIIB) Q4 CY2025 Highlights:

**Revenue:** $2.28 billion vs analyst estimates of $2.20 billion (7.1% year-on-year decline, 3.6% beat)

**Adjusted EPS:** $1.99 vs analyst estimates of $1.63 (22.1% beat)

**Adjusted EBITDA:** $795.5 million vs analyst estimates of $396.5 million (34.9% margin, significant beat)

**Adjusted EPS guidance for the upcoming financial year 2026** is $15.75 at the midpoint, beating analyst estimates by 5.3%

**Operating Margin:** 4.3%, down from 18% in the same quarter last year

**Market Capitalization:** $28.69 billion

While we enjoy listening to the management’s commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From Biogen’s Q4 Earnings Call

**Alex Hammond (Wolfe Research)** asked about the cadence of sales growth for Lekembi and maintenance adoption; CEO Christopher Viehbacher explained persistency rates and the gradual uptake of subcutaneous formulations, noting reimbursement timing will influence acceleration.

**Phil Nadeau (TD Cowen)** queried when Biogen’s top line could return to growth; Viehbacher stated that new product launches and positive phase three outcomes in lupus and nephrology are needed, with business development also playing a role.

**Brian Skorney (Baird)** sought commentary on the commercial prospects for BIB080 (anti-tau therapy); Viehbacher and Dr. Priya Singhal emphasized the importance of phase two data and the need to demonstrate efficacy and safety before commercial strategies can be defined.

**Salveen Richter (Goldman Sachs)** questioned the level of conviction in ladifilumab’s lupus trials given mixed phase two data; Dr. Singhal cited proof-of-concept evidence, targeted trial design, and pathway relevance as reasons for optimism, while acknowledging inherent risks.

**Brian Abrahams (RBC Capital Markets)** asked about commercial investment and OpEx strategy for upcoming launches; Viehbacher described a focus on talent acquisition and capability building in new therapeutic areas, but does not anticipate a significant impact on overall margin trajectory.

 






Story Continues  

Catalysts in Upcoming Quarters

Looking ahead, the StockStory team will focus on (1) the regulatory outcomes for iClick and high-dose SPINRAZA in the U.S., (2) pivotal phase three trial readouts in lupus and kidney transplant rejection, and (3) execution of selective European launches for products like Xerxuve and Skyclaris. The evolution of reimbursement dynamics, particularly for subcutaneous Alzheimer’s therapies, and continued business development activity will also be critical to monitor.

Biogen currently trades at $195.50, up from $185.36 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it’s free for active Edge members).

Our Favorite Stocks Right Now

The market’s up big this year - but there’s a catch. Just 4 stocks account for half the S&P 500’s entire gain. That kind of concentration makes investors nervous, and for good reason. While everyone piles into the same crowded names, smart investors are hunting quality where no one’s looking - and paying a fraction of the price. Check out the high-quality names we’ve flagged in our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.

Terms and Privacy Policy

Privacy Dashboard

More Info